<?xml version="1.0" encoding="UTF-8"?>
<p>All patients received Bu as part of the preparative regimen. Patients receiving MA conditioning were treated with either Bu 3.2 mg/kg/day (days −7 to −4) and Cy 60 mg/kg/day (days −3 and −2) or Bu 3.2 mg/kg/day (days 5- to −2) and fludarabine (Flu) 30 mg/m
 <sup>2</sup>/day (days −5 to −2). Bu dosing was modified after the fifth dose, if necessary, to achieve a targeted level of 900±100 ng/mL. RIC was with Flu 30 mg/m
 <sup>2</sup>/day (days −6 to −2) and Bu 3.2 mg/kg/day (days −5 and −4). Patients received either T-cell replete bone marrow or granulocyte colony factor-stimulated peripheral blood stem cell grafts. For GvHD prevention, Tac was administered intravenously at a dose of 0.03 mg/kg/day starting on day – 3 to maintain a level of 5-15 ng/mL. MTX was given at the doses of 15 mg/m
 <sup>2</sup> IV on day +1, and 10 mg/m
 <sup>2</sup> IV on days +3, +6 and +11 after hematopoietic stem cell infusion. Toc was infused intravenously at a dose of 8 mg/kg (maximum dose of 800 mg) once on day-1 approximately 24 hours prior to the hematopoietic stem cell infusion, as per Kennedy and colleagues.
 <sup>
  <xref rid="b18-1030717" ref-type="bibr">18</xref>
 </sup>
</p>
